Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Phosphorus containing other than solely as part of an...
Patent
1995-06-05
1997-05-27
Killos, Paul J.
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Phosphorus containing other than solely as part of an...
514215, A01N 5700
Patent
active
056332386
ABSTRACT:
The present invention relates to the use of cholinesterase inhibitors, such as galanthamine, for the preparation of a pharmaceutical composition for counteracting the sedative or hypnotic or respiratory depressive effects of benzodiazepines, substantially without interfering with the anxiolytic, antipsychotic, anticonvulsant, and muscle relaxant activity of benzodiazepines.
Expressed in another manner, the invention relates to a method for counteracting the sedative, hypnotic or respiratory depressive effects of benzodiazepines, substantially without interfering with the above-mentioned anxiolytic and other desired properties of benzodiazepines, comprising administering, to a patient in subjected to benzodiazepine therapy, that is, a patient who receives benzodiazepine, an effective amount of a pharmaceutically acceptable cholinesterase inhibitor.
An aspect of the invention relates to the treatment of schizophrenia, in particular affective or schizoaffective type of schizophrenia, by administering, to a patient suffering from such a condition, an effective amount of a cholinesterase inhibitor, such as galanthamine.
REFERENCES:
Foster, et al. "Physostigmine Reversal Of Diazepam-Induced Depression," Anethesia and Analgasia 56(3):348-352 (May-Jun. 1977).
Vatashsky, et al. "Mechanism Of Antagonism By Physostigmine Of Acute Flunitrazepam Intoxication," Anesthesiology 64(2): 248-252 (1986).
Blitt, et al. "Reversal Of Lorzaepam Delirium By Physostigmine," Anesthesia and Analgesia 54(5): 607-608 (Sep. Oct. 1975).
Lauven, et al. "Flumazenil (Ro 15-1788) and Physostigmine," Resuscitation 16/suppl., 542-548 (1988).
Hoffman, et al. "Cerebrovascular and Cerebral Metabolic Effects of Physostigmine, Midazolam, and a Benzodiazepine Antagonist," Anesthesia and Analgesia 65(6): 639-644 (Jun. 1986).
Pandit, et al. "Physostigmine Fails To Reverse Clinical Psychomotor, or EEG Effects Of Lorazepam," Anesthesia and Analgesia 62(7): 79-685 (Jul. 1983).
Forth, et al. "Allgemein und Spezielle Pharmakologie und Toxikologie," Allgemeine und Spezielle 5th edition, 106-109 1988.
Deutsch, et al. "Acetylcholinesterase Activity in CSF in Schizophrenia, Depression, Alzheimer's Disease, and Normals," Biological Psychiatry , 18(12): 1363-1373 (Dec. 1983).
R.J. Vovin et al., "Correction of Apatho-Abulic Manifestations in the Procesuel Defect with Cholinotropic Preparations," Journal of Neuropathology and Psychiatry, 2. ed., Moscow 1991.
Paskov, Galanthamine, Hdbk. Exp. Pharmac. 79, 653-672, 1986.
Bretagne et al., "Essais Cliniques en Anesth esiologie D'Un Nouvel Anticholinest erasique La Galanthamine," Anesth. Analges, 22, 285-292, 1965.
Wislicki, "Nivalin (Galanthamine Hydrobromide), an Additional Decurarizing Agent, Some Introductory Observations," Brit. J. Anaesth. 39, 963-968, 1967.
Cozanitis et al., "A Comparative Study of Galanthamine Hydrobromide and Atropine/Neostigmine in Conscious Volunteers," Der Anaesthesist, 416-421, 1971.
Thomsen et al., "Selective Inhibition of Human Acetylcholinesterase by Galanthamine In Vitro and In Vivo," Life Sciences, vol. 46, pp. 1553-1558 (1990).
Thomsen et al., "Galanthamine Hydrobromide in a Long-Term Treatment of Alzheimer's Disease," Dementia 1:46-51 (1990).
Thomsen et al., "Estimation of Cholinesterase Activity (EC 3.1.1.7; 3.1.1.8) in Undiluted Plasma and Erythrocytes as a Tool for Measuring In Vivo Effects of Reversible Inhibitors," J. Clin. Chem. Clin. Biochem. 26 469-475 (1988).
Fritze et al., "Erythrocyte Acetylcholinesterase in Psychiatric Disorders and Controls," Biol. Psychiatry, 1987, vol. 22, pp. 1097-1106.
D.S. Janowsky et al., "Cholinomimetic and Anticholinergic Drugs Used to Investigate an Acetylcholine Hypothesis of Affective Disorders and Stress," Drug Development Research, vol. 4, pp. 125-142, 1984.
M.M. Ghoneim, "Antagonism of Diazepam by Physostigmine," Anesthesiology 52:372, 1980.
G. Foster Larson et al., "Physostigmine Reversal of Diazepam-Induced Depression," Anesthesia and Analgesia, vol. 56, No. 3, May-Jun. 1977, pp. 348-352.
E. Vatashsky et al., "Mechanism of Antagonism by Physostigmine of Acute Flunitrazepam Intoxication," Anesthesiology, vol. 64, No. 2, 248-252, 1986.
C. Blitt et al., "Reversal of Lorazepam Delirium by Physostigmine," Anesthesia and Analgesia, vol. 54, No. 5, pp. 607-608, 1975.
P.M. Lauven et al., "Flumazenil (Ro 15-1788) and Physostigmine," Resuscitation, vol. 16, S41-S48, 1988.
W.E. Hoffman et al., "Cerebrovascular and Cerebral Metabolic Effects of Physostigmine, Midazolam, and a Benzodiazepine Antagonist," Anesthesia and Analgesia, vol. 65, No. 6, 639-644, 1986.
U.A. Pandit et al., "Physostigmine Fails to Reverse Clinical, Psychomotor, or EEG Effects of Lorazepam," Anesthesia and Analgesia, vol. 62, No. 7, 679-685, 1983.
W. Forth et al., Allgemeine und Spezielle Pharmakologie und Toxikologie, BG.I. Wissenschaftsverlag, 106-109, 1988.
CA 112:48617 1989.
Medline 85:195065 1985.
CA 110: 51228 1988.
Chemical Abstracts 92:121768q (1980).
Chemical Abstracts 101:16845w (1984).
Deutsch et al. "Acetylcholinesterase Activity in CSF in Schizophrenia, Depression, Alzheimer's Disease, and Normals", Biol. Psych., 18(12):1363-1373, 1983.
LandOfFree
Method for the treatment of schizophrenia does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Method for the treatment of schizophrenia, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Method for the treatment of schizophrenia will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2329161